vs
フォレスターリサーチ（FORR）とNATURES SUNSHINE PRODUCTS INC（NATR）の財務データ比較。上の社名をクリックして会社を切り替えられます
NATURES SUNSHINE PRODUCTS INCの直近四半期売上が大きい（$123.8M vs $101.1M、フォレスターリサーチの約1.2倍）。NATURES SUNSHINE PRODUCTS INCの純利益率が高く（3.3% vs -33.5%、差は36.8%）。NATURES SUNSHINE PRODUCTS INCの前年同期比売上増加率が高い（4.7% vs -6.5%）。NATURES SUNSHINE PRODUCTS INCの直近四半期フリーキャッシュフローが多い（$7.6M vs $-4.3M）。過去8四半期でNATURES SUNSHINE PRODUCTS INCの売上複合成長率が高い（5.6% vs 0.5%）
フォレスターリサーチは世界的な調査・アドバイザリー企業で、業界調査、経営コンサルティング、業界イベントの開催を主な事業としています。顧客にはグローバル大手企業、テクノロジー企業、消費財分野の代表的企業が含まれ、本社は米国マサチューセッツ州ケンブリッジに置かれています。
Natures Sunshine Products, Inc.（通称NSP）は、ハーブ、ビタミン、ミネラルを含む栄養補助食品やスキンケアなどのパーソナルケア製品の製造を行っています。本社はユタ州リーハイに置き、同州スパニッシュフォークに生産拠点を構えています。
FORR vs NATR — 直接比較
損益計算書 — Q4 FY2025 vs Q4 FY2025
| 指標 | | |
|---|---|---|
| 売上 | $101.1M | $123.8M |
| 純利益 | $-33.9M | $4.1M |
| 粗利率 | 56.7% | 72.5% |
| 営業利益率 | -36.6% | 4.3% |
| 純利益率 | -33.5% | 3.3% |
| 売上前年比 | -6.5% | 4.7% |
| 純利益前年比 | -7941.4% | 1379.4% |
| EPS（希薄化後） | $-1.75 | $0.23 |
緑 = その指標でリード。会計年度がずれている場合は期間が異なる場合あり
8四半期 売上・利益トレンド
並べて比較する四半期履歴。決算期がずれていても暦四半期で整列
| Q4 25 | $101.1M | $123.8M | ||
| Q3 25 | $94.3M | $128.3M | ||
| Q2 25 | $111.7M | $114.8M | ||
| Q1 25 | $89.9M | $113.2M | ||
| Q4 24 | $108.0M | $118.2M | ||
| Q3 24 | $102.5M | $114.6M | ||
| Q2 24 | $121.8M | $110.6M | ||
| Q1 24 | $100.1M | $111.0M |
| Q4 25 | $-33.9M | $4.1M | ||
| Q3 25 | $-2.1M | $5.3M | ||
| Q2 25 | $3.9M | $5.3M | ||
| Q1 25 | $-87.3M | $4.7M | ||
| Q4 24 | $432.0K | $-321.0K | ||
| Q3 24 | $-5.8M | $4.3M | ||
| Q2 24 | $6.3M | $1.3M | ||
| Q1 24 | $-6.7M | $2.3M |
| Q4 25 | 56.7% | 72.5% | ||
| Q3 25 | 60.0% | 73.3% | ||
| Q2 25 | 55.5% | 71.7% | ||
| Q1 25 | 55.9% | 72.1% | ||
| Q4 24 | 58.8% | 72.0% | ||
| Q3 24 | 60.5% | 71.3% | ||
| Q2 24 | 57.3% | 71.4% | ||
| Q1 24 | 54.9% | 71.2% |
| Q4 25 | -36.6% | 4.3% | ||
| Q3 25 | 4.7% | 7.0% | ||
| Q2 25 | 6.2% | 3.7% | ||
| Q1 25 | -97.5% | 5.4% | ||
| Q4 24 | -0.5% | 3.8% | ||
| Q3 24 | -0.7% | 4.6% | ||
| Q2 24 | 9.3% | 5.1% | ||
| Q1 24 | -9.3% | 4.2% |
| Q4 25 | -33.5% | 3.3% | ||
| Q3 25 | -2.3% | 4.2% | ||
| Q2 25 | 3.5% | 4.6% | ||
| Q1 25 | -97.1% | 4.2% | ||
| Q4 24 | 0.4% | -0.3% | ||
| Q3 24 | -5.7% | 3.8% | ||
| Q2 24 | 5.2% | 1.2% | ||
| Q1 24 | -6.7% | 2.1% |
| Q4 25 | $-1.75 | $0.23 | ||
| Q3 25 | $-0.11 | $0.30 | ||
| Q2 25 | $0.20 | $0.28 | ||
| Q1 25 | $-4.62 | $0.25 | ||
| Q4 24 | $0.02 | $-0.02 | ||
| Q3 24 | $-0.30 | $0.23 | ||
| Q2 24 | $0.33 | $0.07 | ||
| Q1 24 | $-0.35 | $0.12 |
貸借対照表と財務力
直近四半期の流動性・レバレッジ・純資産のスナップショット
| 指標 | | |
|---|---|---|
| 現金・短期投資手元流動性 | $63.3M | $93.9M |
| 総負債低いほど良い | — | — |
| 株主資本純資産 | $126.5M | $161.6M |
| 総資産 | $404.0M | $261.1M |
| 負債/資本比率低いほどレバレッジが低い | — | — |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $63.3M | $93.9M | ||
| Q3 25 | $65.1M | $95.6M | ||
| Q2 25 | $67.8M | $81.3M | ||
| Q1 25 | $75.6M | $86.5M | ||
| Q4 24 | $56.1M | $84.7M | ||
| Q3 24 | $62.8M | $78.7M | ||
| Q2 24 | $58.9M | $68.7M | ||
| Q1 24 | $61.4M | $77.8M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $2.1M |
| Q4 25 | $126.5M | $161.6M | ||
| Q3 25 | $157.7M | $166.7M | ||
| Q2 25 | $159.5M | $163.7M | ||
| Q1 25 | $147.4M | $167.1M | ||
| Q4 24 | $229.5M | $161.0M | ||
| Q3 24 | $234.3M | $162.6M | ||
| Q2 24 | $237.1M | $156.4M | ||
| Q1 24 | $230.9M | $159.7M |
| Q4 25 | $404.0M | $261.1M | ||
| Q3 25 | $414.2M | $264.8M | ||
| Q2 25 | $436.0M | $254.9M | ||
| Q1 25 | $439.8M | $252.7M | ||
| Q4 24 | $503.9M | $240.9M | ||
| Q3 24 | $505.3M | $245.3M | ||
| Q2 24 | $524.2M | $235.8M | ||
| Q1 24 | $555.7M | $247.3M |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | 0.01× |
キャッシュフローと資本効率
再投資後に実際に生み出すキャッシュ。純利益より操作が難しい
| 指標 | | |
|---|---|---|
| 営業キャッシュフロー直近四半期 | $-3.2M | $9.9M |
| フリーキャッシュフロー営業CF - 設備投資 | $-4.3M | $7.6M |
| FCFマージンFCF / 売上 | -4.2% | 6.1% |
| 設備投資強度設備投資 / 売上 | 1.1% | 1.9% |
| キャッシュ転換率営業CF / 純利益 | — | 2.41× |
| 直近12ヶ月FCF直近4四半期 | $18.1M | $28.8M |
8四半期トレンド — 暦四半期で整列
| Q4 25 | $-3.2M | $9.9M | ||
| Q3 25 | $1.2M | $18.5M | ||
| Q2 25 | $-3.6M | $4.3M | ||
| Q1 25 | $26.7M | $2.6M | ||
| Q4 24 | $-1.8M | $12.2M | ||
| Q3 24 | $264.0K | $9.6M | ||
| Q2 24 | $-2.9M | $1.3M | ||
| Q1 24 | $611.0K | $2.2M |
| Q4 25 | $-4.3M | $7.6M | ||
| Q3 25 | $524.0K | $16.8M | ||
| Q2 25 | $-4.2M | $3.0M | ||
| Q1 25 | $26.1M | $1.5M | ||
| Q4 24 | $-2.5M | $10.0M | ||
| Q3 24 | $-223.0K | $7.9M | ||
| Q2 24 | $-3.7M | $-2.0M | ||
| Q1 24 | $-815.0K | $-1.5M |
| Q4 25 | -4.2% | 6.1% | ||
| Q3 25 | 0.6% | 13.1% | ||
| Q2 25 | -3.8% | 2.6% | ||
| Q1 25 | 29.0% | 1.3% | ||
| Q4 24 | -2.3% | 8.5% | ||
| Q3 24 | -0.2% | 6.9% | ||
| Q2 24 | -3.1% | -1.9% | ||
| Q1 24 | -0.8% | -1.4% |
| Q4 25 | 1.1% | 1.9% | ||
| Q3 25 | 0.7% | 1.3% | ||
| Q2 25 | 0.5% | 1.2% | ||
| Q1 25 | 0.7% | 1.0% | ||
| Q4 24 | 0.6% | 1.9% | ||
| Q3 24 | 0.5% | 1.5% | ||
| Q2 24 | 0.7% | 3.0% | ||
| Q1 24 | 1.4% | 3.3% |
| Q4 25 | — | 2.41× | ||
| Q3 25 | — | 3.46× | ||
| Q2 25 | -0.93× | 0.81× | ||
| Q1 25 | — | 0.55× | ||
| Q4 24 | -4.24× | — | ||
| Q3 24 | — | 2.21× | ||
| Q2 24 | -0.46× | 0.97× | ||
| Q1 24 | — | 0.94× |
財務フロー比較
売上 → 粗利 → 営業利益 → 純利益のサンキー図
セグメント別売上内訳
FORR
| Research Segment | $82.2M | 81% |
| Consulting Segment | $16.2M | 16% |
| Billable Expenses | $1.5M | 2% |
| Professional Services | $1.4M | 1% |
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
